Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

Older adults who are admitted to the hospital with their first ischemic stroke who have poor nutritional status upon admission have a higher risk of post-stroke myocardial injury, a study shows.

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...

A study has found that patients with ischemic stroke and COVID-19, compared with patients without COVID-19, experience worse recovery outcomes.

Smoking and high-intensity smoking are associated with cryptogenic ischemic stroke (CIS) among adults aged 18 to 45 years.